1. Home
  2. ESS vs HALO Comparison

ESS vs HALO Comparison

Compare ESS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Essex Property Trust Inc.

ESS

Essex Property Trust Inc.

N/A

Current Price

$269.51

Market Cap

17.6B

Sector

Real Estate

ML Signal

N/A

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

N/A

Current Price

$92.99

Market Cap

14.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ESS
HALO
Founded
1971
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.6B
14.8B
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
ESS
HALO
Price
$269.51
$92.99
Analyst Decision
Hold
Buy
Analyst Count
26
9
Target Price
★ $295.18
$119.89
AVG Volume (30 Days)
514.1K
★ 2.0M
Earning Date
10-27-2026
11-05-2026
Dividend Yield
★ 3.78%
N/A
EPS Growth
★ N/A
N/A
EPS
2.62
★ 5.12
Revenue
★ $1,887,345,000.00
$151,862,000.00
Revenue This Year
$1.09
$35.97
Revenue Next Year
$3.67
$14.85
P/E Ratio
$103.00
★ $18.84
Revenue Growth
★ 6.36
N/A
52 Week Low
$238.46
$61.23
52 Week High
$303.35
$134.00

Technical Indicators

Market Signals
Indicator
ESS
HALO
Relative Strength Index (RSI) 47.28 20.69
Support Level $268.06 $64.08
Resistance Level $277.17 $111.15
Average True Range (ATR) 5.15 4.69
MACD 0.15 -2.96
Stochastic Oscillator 56.70 2.89

Price Performance

Historical Comparison
ESS
HALO

About ESS Essex Property Trust Inc.

Essex Property Trust owns a portfolio of 258 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: